GleamWall
中文EN

ORMP ORAMED PHARMACEUTICALS INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1176309 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY435.3%
TTM EPS YoY412.5%
Revenue 3-yr CAGR-11.9%
Net income 3-yr CAGR—

Margins

Gross margin0.7%
Operating margin-754.4%
Net margin3,202.5%
FCF margin-457.7%
EBITDA margin-748.4%

Returns

ROE37.0%
ROA33.2%
ROIC (approx.)-10.4%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets13.5%
Debt / equity0.00x
Current ratio6.98x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.14x
Accruals ratio37.9%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2.00M—
Cost of revenue$1.99M—
Gross profit$13,000—
R&D expense$6.38M$6.32M
SG&A expense$8.72M$6.46M
Operating income-$15.09M-$12.78M
Interest expense—$853,000
Pretax income$75.32M-$15.92M
Income tax$11.31M$3.18M
Net income$64.05M-$19.06M
EBITDA-$14.97M-$12.59M
EPS (basic)1.53-0.48
EPS (diluted)1.50-0.48
Dividends declared per share0.25—
Weighted avg. shares (diluted)42.42M40.85M
Balance sheet
Cash & equivalents$45.95M$54.42M
Short-term investments$5.42M$3.44M
Current assets$133.27M$143.22M
PP&E, net$586,000$698,000
Total assets$230.86M$155.28M
Current liabilities$19.09M$5.68M
Total liabilities$31.12M$9.93M
Shareholders' equity$199.74M$146.26M
Shares outstanding39.28M39.92M
Cash flow statement
Operating cash flow-$9.14M-$8.41M
Capital expenditure$9,000$18,000
Free cash flow-$9.15M-$8.43M
Investing cash flow$5.44M$105.82M
Financing cash flow-$4.74M-$52.04M
Depreciation & amortization$121,000$193,000
Stock-based compensation$5.99M$4.05M
Share buybacks$4.74M$2.48M

Free plan shows the latest 2 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.